(Reuters) - Impax Laboratories Inc said the U.S. Food and Drug Administration raised concerns about the company's factory in Taiwan, casting in doubt the future of its Parkinson's drug, rytary. Shares of Impax, which makes generics and specialty drugs to treat central nervous system disorders, fell as much as 17 percent on Tuesday, after the regulator listed 10 violations at the plant. The FDA had rejected the company's patented long-acting capsule to treat the symptoms of Parkinson's disease in January last year, citing lingering manufacturing issues at Impax's Hayward plant in California. After that rejection, the company cut its volumes at the Hayward factory and made its Taiwan plant the primary facility for rytary. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment